Foundayo shows significant weight reduction in older adults with obesity in new analysis
Foundayo (orforglipron) demonstrated up to 13% body weight reduction in adults aged 65 and older with obesity.
Therapeutic Area
Therapeutic area intelligence for Oral GLP-1 receptor agonist with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.